News

Filter by Category
Filter by Year

Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline

  • Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies
  • Single-target license with upfront and milestone payments plus royalties
  • First Synaffix partnership announced with a Korean company

THE NETHERLANDS and SOUTH KOREA, 6 February 2023 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Chong Kun Dang Pharm (CKD), a global pharmaceutical company based in South Korea, today announce that they have entered a licensing agreement.

The agreement provides CKD a license for global, target-specific rights to Synaffix’s proprietary ADC technology, adding a new ADC drug candidate to CKD’s pipeline. CKD will have access to Synaffix’s ADC technologies, comprising GlycoConnect™, HydraSpace™ and an undisclosed linker-payload from the toxSYN™ platform. Under the terms of the agreement, Synaffix has received an upfront payment and is eligible to receive further milestone payments plus royalties on commercial sales. CKD will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.

“Scientific rigor and a growing body of promising underlying data have led us to this exciting moment where we can bring a new ADC into the development pipeline of CKD Pharm.  We value the strong experience of the CKD team within the oncology space and look forward to building on this further as we continue our close and long-standing collaboration aimed at bringing this promising new drug candidate to patients in need.”

Peter van de Sande, Chief Executive Officer of Synaffix

“By combining our existing oncology expertise and related technologies with the ADC platform of Synaffix, we have been able to efficiently establish a novel ADC candidate for CKD’s pipeline. CKD’s work is deeply rooted in oncology, and we are committed to improving the quality of life for patients by developing highly targeted novel drugs for the treatment of cancer.”

Young-Joo, Kim, Chief Executive Officer of CKD Pharm

RM Global Partners LLC and DLA Piper LLP (US) acted as CKD’s advisors for this transaction.

Join Mailing List

Copyright Synaffix BV 2021. All Rights Reserved

Protein Conjugates

Bring your own and/or choose from the following categories. 

 

Just like our ADC technology, we can easily attach peptide and protein-based payloads to your antibody.

 

Early preclinical data available on request.

Bring Your Own

scFv / Fab
Cytokine

Immune Cell Recruiters

Anti-CD3

T cell recruitment
IL-15

NK cell recruitment

IL-15 Receptor Fusion

NK cell recruitment

HydraSpace™ Polar Spacer

Forming an integral part of every toxSYN™ linker-payload, HydraSpace™ bears a negative charge at physiological pH and improves:

  1. Therapeutic efficacy
  2. Tolerability
  3. PK
  4. Manufacturability
Key publication about HydraSpace

GlycoConnect™ design easily matches payload potency with the most appropriate drug-antibody ratio (DAR).

Key publications about GlycoConnect™

toxSYN™ Linker-Payloads

Choose from the following linker-payloads, attach to your antibody under a technology evaluation and go straight into ADC product development following positive POC.
toxSYN™
Linker-Payload
Mode-of-Action Payload
(Active Catabolite)
1. SYNtecan E™*Topoisomerase 1 inhibitor Camptothecin-based
2. SYNeamicin D™*DNA
damaging agent
Calicheamicin-based
3. SYNeamicin G™*
4. SYN-PNU™*Nemorubicin-based
5. SYNstatin E™Microtubule
inhibitors
Auristatin-based
6. SYNstatin F™
7. SYNtansine™ Maytansine-based

* Patent protection filed by Synaffix, beyond the claims of GlycoConnect™ and HydraSpace™

** N-6-aminohexanoyl-maytansine (Ahx-maytansine)